News

Immuneel Therapeutics has launched Qartemi, a cutting-edge CAR T-cell therapy aimed at treating adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL). This personalized therapy marks a significant milestone in India's cancer treatment landscape, particularly in the realm of immunotherapy.

Addressing a Critical Gap in Cancer Care

The company states that Qartemi is designed to address the unmet medical need for advanced cancer treatments in India, where conventional therapies such as chemotherapy often fail to provide effective results for patients with resistant forms of B-NHL. By offering this therapy locally, Immuneel is providing patients access to a treatment that is benchmarked to global standards, bringing renewed hope to those battling this challenging condition.

The Rising Burden of Blood Cancers in India

India faces an alarming increase in blood cancer cases, with approximately 120,000 new cases and over 70,000 deaths annually attributed to leukemia, lymphoma, and multiple myeloma. For patients struggling with these diseases, especially those with relapsed or refractory B-NHL, advanced therapies like CAR T-cell treatment are becoming increasingly critical. Qartemi represents a lifeline for patients, embodying the need for innovation in cancer care.

Bridging the Gap in India’s Cancer Immunotherapy Landscape

Since its inception in 2019, Immuneel Therapeutics has dedicated itself to addressing the unmet needs of cancer care in India. With Qartemi, the flagship CAR T-cell therapy, the company aims to transform cancer treatment in India by providing globally advanced, personalized therapies at an affordable cost. Qartemi is a key part of the company’s mission to offer lifesaving therapies for cancer that have previously been inaccessible in India.

A Critical Moment in India’s Fight Against Cancer

The launch of Qartemi signifies a pivotal moment in India's battle against aggressive blood cancers. Dr. Siddhartha Mukherjee, Board Director and Co-Founder of Immuneel Therapeutics, highlighted the importance of combining world-class CAR T-cell research with indigenous manufacturing to create a breakthrough that redefines cancer care in India.

By bringing globally benchmarked CAR-T cell therapy to India, the firm is providing a breakthrough treatment and redefining what is possible in precision medicine. This is a critical step in ensuring that advanced, life-saving therapies are within reach for patients who need them most.

Pioneering CAR T-Cell Therapy Research in India

Immuneel has been at the forefront of CAR T-cell therapy development in India. The company initiated India’s first CAR T-cell therapy clinical trial in 2022. This trial focused on a novel autologous CD19-directed CAR T-cell therapy for patients with relapsed or refractory B-cell malignancies, paving the way for the introduction of Qartemi.

Collaborations with Leading Hospitals

To ensure widespread access to Qartemi, Immuneel has partnered with a network of renowned hospitals across India. These include:

• Narayana Health
• Apollo Hospitals
• CMC Vellore & Ludhiana
• Manipal Hospitals
• Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) Delhi
• SGPGI Lucknow
• Amrita Hospital Faridabad
• HOC Vedanta Ahmedabad
• Cytecare Bangalore
• Sparsh Bangalore
• Marengo Asia Hospitals

Through these partnerships, the therapy is now accessible to patients across the country, enabling them to receive world-class cancer care without needing to travel abroad.

A New Era in Cancer Immunotherapy

Qartemi’s launch marks a paradigm shifts in India’s cancer immunotherapy landscape, providing a much-needed advanced treatment option for blood cancer patients. Immuneel Therapeutics is committed to advancing cancer care and improving patient outcomes through innovation, research, and collaboration.

With the increasing prevalence of blood cancers in India, the introduction of Qartemi highlights the growing importance of locally available, globally competitive therapies to combat these life-threatening diseases effectively.